Sagent (SGNT) Launches Flumazenil Injection
Tweet
Share
E-mailGet Alerts SGNT Hot Sheet
Join SI Premium – FREE
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) announced the launch of Flumazenil Injection, USP, a benzodiazepine antagonist, in two latex-free vial presentations. According to IMS for the 12 months ending September 2012, the US market for Flumazenil Injection, USP approximated $5.6 million. As with all products in Sagent's portfolio, Flumazenil features the Company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- CoVolt Power files for proposed IPO
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
